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Variable alterations of the 
microbiota, without metabolic or 
immunological change, following 
faecal microbiota transplantation 
in patients with chronic pouchitis
J. Landy1,2, A. W. Walker3,4, J. V. Li5, H. O. Al-Hassi2, E. Ronde2, N. R. English2, E. R. Mann2, 
D. Bernardo2, S. D. McLaughlin6, J. Parkhill3, P. J. Ciclitira7, S. K. Clark8, S. C. Knight2 & 
A. L. Hart1,2
Faecal microbiota transplantation (FMT) is effective in the treatment of Clostridium difficile infection, 
where efficacy correlates with changes in microbiota diversity and composition. The effects of FMT 
on recipient microbiota in inflammatory bowel diseases (IBD) remain unclear. We assessed the effects 
of FMT on microbiota composition and function, mucosal immune response, and clinical outcome 
in patients with chronic pouchitis. Eight patients with chronic pouchitis (current PDAI ≥7) were 
treated with FMT via nasogastric administration. Clinical activity was assessed before and four weeks 
following FMT. Faecal coliform antibiotic sensitivities were analysed, and changes in pouch faecal and 
mucosal microbiota assessed by 16S rRNA gene pyrosequencing and 1H NMR spectroscopy. Lamina 
propria dendritic cell phenotype and cytokine profiles were assessed by flow cytometric analysis 
and multiplex assay. Following FMT, there were variable shifts in faecal and mucosal microbiota 
composition and, in some patients, changes in proportional abundance of species suggestive of 
a “healthier” pouch microbiota. However, there were no significant FMT-induced metabolic or 
immunological changes, or beneficial clinical response. Given the lack of clinical response following 
FMT via a single nasogastric administration our results suggest that FMT/bacteriotherapy for 
pouchitis patients requires further optimisation.
Inflammatory bowel diseases (IBD) occur as the result of an aberrant inter-relationship between the 
intestinal microbiota and host immune system in genetically predisposed individuals1,2. Modification of 
the microbiota is an emerging option for therapeutic purposes3. Some of the most compelling evidence 
for the clinical efficacy of altering the microbiota in IBD is derived from studies of pouchitis4, where 
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intestinal inflammation occurs in the ileal reservoir after a restorative proctocolectomy (RPC) for ulcerative 
colitis (UC).
Microbiological data implicate a dysbiosis (i.e. an alteration in the composition of the microbiota 
to one that is deleterious to host health) in the pathogenesis of pouchitis, although a unifying or char-
acteristic dysbiosis has not been demonstrated5–7. Clinical data confirm a role for antibiotics and pro-
biotics for the treatment of acute and chronic pouchitis8–14. However, a proportion of patients either 
does not respond to antibiotic therapy, or become antibiotic dependent. Long term treatment with 
antibiotics may lead to the development of antibiotic resistance and promotion of extended spectrum 
beta-lactamase-producing (ESBL) bacteria15. Clinical studies report limited benefit for maintenance of 
remission with the probiotic combination, VSL#316,17.
An alternative approach to conventional probiotics is transplantation of the entire “organ” of the gut 
microbiota from a healthy donor. Faecal microbiota transplantation (FMT) is effective in the treatment of 
recurrent Clostridium difficile infection, where resolution of disease is tightly linked to post-FMT changes 
in microbiota diversity and composition18. The effects of FMT on the recipient microbiota in Clostridium 
difficile and other gastrointestinal as well as metabolic conditions are durable19,20. Case reports and small 
case series have suggested positive clinical outcomes following FMT in IBD20–23. However, recent studies 
of FMT in UC did not demonstrate clinical efficacy and suggest variable efficiency of colonisation by 
the donors’ microbiota24,25. More recently, two randomised studies of FMT in active UC demonstrated 
conflicting clinical outcomes26,27. The ability of FMT to colonise the recipient microbial environment in 
the context of chronic inflammation remains unclear. To our knowledge, no studies have assessed the 
functional metabolic and immunological effects of FMT in the context of IBD.
Lamina propria dendritic cells (DC) are pivotal in the interactions between the host immune system 
and the gut microbiota due to their innate bacterial sensing properties and antigen sampling capacity28. 
Altered DC phenotype and function in IBD suggests that they contribute to inflammatory processes in 
response to the microbiota28,29. Probiotics and prebiotics have been shown to alter mucosal innate and 
adaptive immune responses, particularly DC function, in IBD30–32.
We hypothesised that FMT would induce clinical response in patients with chronic pouchitis, altering 
the composition and function of the pouch microbiota and elicit immunoregulatory effects. We aimed 
to assess the effect of FMT on the microbiota composition and function, in addition to effects on the 
mucosal immune response, particularly on DC, and assess the clinical response in patients with chronic 
pouchitis.
Results
Patient characteristics. Ten patients were recruited to the study. One withdrew prior to FMT. 
Another patient was diagnosed with adenocarcinoma of the rectal cuff at the screening pouchoscopy 
and did not proceed to FMT. Of the eight remaining patients studied, five were female. The median age 
was 46 years (range 24–63 years). The median number of years since restorative proctocolectomy (RPC) 
was 10 years (range 4–22 years) (Table 1).
Alterations in antibiotic sensitivity post FMT. Ciprofloxacin resistant coliforms were detected in 
faecal samples from four patients. In three patients stool testing detected ESBL-coliforms (Table 1). In 
two patients who tested positive for ciprofloxacin-resistant coliforms in their stool samples prior to FMT 
(patients 3 and 5), coliforms regained sensitivity to ciprofloxacin post FMT. For these patients, regaining 
sensitivity to ciprofloxacin enabled further effective antimicrobial therapy during their on-going disease 
management.
Clinical efficacy. There were no major adverse events following FMT. Three patients reported rela-
tively minor adverse effects including nausea (n = 3); vomiting (n = 1); bloating (n = 2); fever (n = 1). All 
adverse events were transient, lasting less than 24 hours. However, following FMT, no patients achieved 
Patient Sex
Time since 
RPC (years)
Pouch 
type
Pre-pouch 
ileitis
ESBL 
coliforms
Ciprofloxacin 
sensitive coliforms
1 F 6 J Yes No Yes
2 F 6 J Yes No No
3 F 10 J Yes Yes No
4 F 22 W Yes No Yes
5 M 16 J Yes Yes No
6 M 22 W Yes Yes No
7 M 4 J Yes No Yes
8 F 4 J Yes No Yes
Table 1.  Patient characteristics.
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clinical remission. Two patients (patients 2 and 3) demonstrated a reduction of total PDAI score by ≥ 3 
points at 4 weeks post FMT. However, both patients still had a total PDAI score ≥ 7 at 4 weeks post 
FMT. There were no changes in Cleveland global quality of life (QoL) score (Supplementary Figure 1).
Microbiota analysis. A total of 156,963 sequences were generated, with an average of 3982 reads per 
sample (range 391–12,592). Just over 1,000 operational taxonomic units (OTUs) were detected, with most 
sequences derived from the bacterial phyla Firmicutes (57%), Bacteroidetes (26%), Proteobacteria (14.5%) 
and Actinobacteria (1.6%) (Supplementary Figure 2). A total of 105 bacterial families were detected in 
samples, and 15 of these accounted for more than 90% of the total OTUs in the whole dataset (Fig. 1, 
Supplementary Figure 3).
Donor and patient samples at baseline. There was significant inter-individual variation in micro-
biota content, in both the donors and pouch patients. Despite this, some general trends were observed. 
At the Phylum level, prior to FMT, pouchitis patient stool samples were characterised by a higher propor-
tion of Proteobacteria (p = 0.0047) compared with donor stool samples (Supplementary Figure 2). At the 
Family level, patient stool samples prior to FMT were characterised by a lower proportion of common 
obligate anaerobic lineages such as Ruminococcaceae (p = < 0.0001), Coriobacteriaceae (p = < 0.0001), 
Porphyromonadaceae (p = 0.0003) and Rikenellaceae (p = 0.0007), and higher proportional abun-
dances of Enterobacteriaceae (p = 0.004) and Clostridiaceae (p = 0.0097). (Supplementary Figure 3). 
Finally, when looking at the Genus and 97% operational taxonomic unit (OTU) levels, patient stool 
samples prior to FMT contained lower proportional abundances of many obligate anaerobes, including 
Faecalibacterium prausnitzii (p = 0.0002), and higher proportions of Escherichia/Shigella spp. (p = 0.0019) 
and Ruminococcus gnavus (p = 0.0029) compared with donor stool samples. (Supplementary Table 1).
Patient stool prior to FMT was characterised by low bacterial richness (observed OTUs p = 0.001) and 
diversity (Shannon diversity index p = 0.001; inverse Simpson diversity index p = 0.02; Chao 1 estimate 
of overall diversity p = 0.0003) compared with donor stool samples (Supplementary Figure 4).
Changes in microbiota composition post faecal transplantation. There were no overall changes 
in bacterial richness or diversity of the faecal or mucosal microbiota post FMT (Supplementary Figure 
4). However, Non-metric multidimensional scaling (NMDS) analysis using the Bray Curtis calculator, 
which measures dissimilarity in microbial community structure between samples by comparing overlap-
ping OTU membership and their relative abundances, indicated a shift in both the stool and mucosal 
microbiota towards a composition with greater similarity to donor stool following FMT (Fig. 2). AMOVA 
analysis using the Yue and Clayton calculator, which also takes into account OTU membership and 
relative abundances when comparing bacterial community structures also suggested less difference 
between recipient and donor microbiota compositions following FMT (Donor vs recipient faeces pre 
FMT p = 0.005; Donor vs recipient faeces post FMT p = 0.034; Donor vs recipient biopsy pre FMT 
p = 0.003; Donor vs recipient biopsy post FMT p = 0.174).
The significant inter-individual variation of the baseline faecal and mucosal microbiota was also 
reflected in the varying responses following FMT by each of the recipient patients (Supplementary Figures 
5). Broadly, Patients 2 and 3 showed a shift in their faecal and mucosal microbiota towards that of their 
respective donor’s stool following FMT. Patient 5 showed a shift in the faecal and mucosal microbiota 
Figure 1. Analysis of bacterial families in stool and biopsy samples pre and post FMT. Percentage of 
sequences identified from the bacterial families of > 1% total relative abundance in: (A) patient stool samples 
pre (n = 7) and post FMT (n = 8); (B) patient mucosal samples pre (n = 8) and post FMT (n = 5).
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post FMT, although this shift was not towards a similar microbiota to Donor 5. Patients 1 and 4 showed 
a slight shift in the composition of their faecal microbiota, but not of their mucosal microbiota. Patients 
6, 7 and 8 showed no shift in either stool or mucosal microbiota following FMT. There was an increased 
proportion of Ruminococcaceae with a concomitant reduction in the proportion of Enterobacteriaceae in 
the samples post FMT in patients 2, 3, 4 and 5 (Supplementary Figure 5).
When averaging across the whole study cohort, Escherichia coli/Shigella spp. (p = 0.0051) and 
Ruminococcus gnavus (p = 0.0097) were reduced in proportional abundance in stool samples from 
patients post FMT, and there was an increase in relative abundance of Sutterella stercoricanis (p = 0.0024) 
and Dorea longicatena (p = 0.014) as well as a trend towards increased proportional abundance of 
Faecalibacterium prauznitzii (p = 0.0897). However, inter-individual variation was marked, and adjusting 
significance threshold levels to allow for false discovery rate using the Benjamini-Hochberg method sug-
gested that none of these observations were significant. In biopsy samples the only significant difference 
at all taxonomic levels following FMT was a reduction in the proportional abundance of Enterococcus 
spp. (p = 0.001) but this group was not dominant in the mucosal microbiota pre-FMT (mean of 0.1% 
proportional abundance), and the p value only just reached the Benjamini-Hochberg corrected signifi-
cance threshold. (Fig. 1) (Supplementary Table 2).
1H NMR spectroscopy-based metabonomic analysis of faecal samples from donors and 
patients. Results generated from fresh faecal water and dried faecal samples were similar. Strong 
metabolic differences were found between donors and patients after multiple test correction (Fig. 3). 
Higher levels of formate (p = 0.02), phenylalanine (p = 0.01), tyrosine (p = 0.02), leucine (p = 0.02), ala-
nine (p = 0.02) and histamine (p = 0.002) (putatively assigned based on database correlation) were found 
in the patients in contrast to donors, whereas concentrations of uracil (p = 0.0006), fumarate (p = 0.01) 
and valerate (p = 0.006) were higher in donors (Fig. 3B) with a trend towards a higher level of acetate 
and butyrate in donors compared with patients. The variation in the metabolic data was demonstrated in 
the PCA scores plot, where samples sharing similar metabolic features cluster together. In the PCA scores 
plots (Fig. 3A), patients both pre- and post-FMT exhibited greater heterogeneity than donors. However, 
no significant metabolic changes in patients pre- and post-FMT (Fig. 3A ii) was observed as reflected by 
the negative values of Q2Y, a parameter describing the goodness of prediction.
Metabolic profiles of faecal water reveal the metabolites derived from the gut bacteria and the interac-
tions between the host and bacteria. Therefore, we investigated the host-microbial crosstalk by integrating 
Figure 2. Non-metric multidimensional scaling (NMDS) analysis for donor and patient samples pre 
and post FMT. NMDS analysis, calculated in mothur using the Bray Curtis calculator, of donor stool (x) 
and patient stool pre FMT (open squares) and post FMT (filled squares) and patient mucosal samples pre 
FMT (open circles) and post FMT (filled circles) for each patient and donor. Oval shows distinct clustering 
of healthy donor faecal microbiota sample profiles in comparison to the pouchitis patient samples, arrows 
indicate directional shifts in patient samples post FMT.
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1H NMR data with microbial profiles using O-PLS regression analysis. Of 17 selected bacterial groups, 
Porphyromonadaceae and unclassified Firmicutes levels showed positive correlative relationships with 
higher concentration of short chain fatty acids, uracil, fumarate and reverse correlation with lactate, 
succinate and histamine (Q2Y values of OPLS models are 0.52 and 0.43, respectively).
Innate immune characteristics following FMT. There were also no significant changes after 
FMT in dendritic cell expression of TLR 2 (p = 0.3), TLR 4 (p = 0.2) or TLR 5 (p = 0.6). There were 
no significant changes in dendritic cell expression of homing markers β 7 (p = 0.4) or CCR 9 (p = 0.8) 
before and after FMT or expression of the activation marker CD40 (p = 0.3) (Supplementary Figure 6). 
Furthermore, there was no significant reduction in the level of IL-6 (p = 0.5) or TNFα (p = 0.3) in the 
biopsy supernatants after FMT.
Discussion
We report the first study of FMT in patients with chronic pouchitis that incorporates clinical, immu-
nological, and both taxonomic and functional microbiological assessments. Our study suggests that 
administration of a single nasogastrically delivered FMT from a healthy donor results in some shift in 
the composition of the microbiota, and in some cases with specific changes in the abundance of species 
suggestive of a “healthier” pouch microbiota. However, microbiota engraftment success varied greatly 
between recipients. Regardless of engraftment success, FMT did not appear to result in significant func-
tional change of the microbiota, mucosal immunological response or clinical efficacy.
Patients’ faecal microbiota differed significantly from healthy donors’ faecal microbiota, including 
reduced proportional abundances of Faecalibacterium prausnitzii, which has repeatedly been shown to be 
reduced in IBD patients and may have some anti-inflammatory properties33. This may be due to differ-
ences between the colonic and the pouch environment as well as disease specific differences. While many 
features of this dysbiosis may be driven by disease it is also possible that some may have resulted from 
prior antibiotic use. For practical and ethical reasons, we were only able to impose an antibiotic exclusion 
period of two weeks prior to FMT, and it has been shown previously that post-antibiotic microbiota 
perturbations can remain for longer periods than this34. However, ileal pouch faecal microbiota shifts 
towards a “colon-like” community following ileostomy closure35 and baseline pouch samples demon-
strated findings in keeping with previous reports of dysbiosis in IBD and specifically pouchitis5–7,24,25,36.
Numerous studies document the association between increased Proteobacteria, specifically Escherichia, 
in IBD37–39. Post FMT, Escherichia were less proportionally abundant in a number of patients’ stools. 
Despite not reaching statistical significance, likely due to the large degree of inter-individual variation 
in microbiota content, other post FMT microbiota changes also suggested a slight overall shift towards 
a healthier bacterial composition. The mucolytic bacterium Ruminococcus gnavus, for example, has been 
Figure 3. 1H NMR-based metabonomic analysis of faecal samples from donors and patients. (A) PCA 
scores plot of 1H NMR profiles of fresh faecal water samples obtained from donors and patients at pre and 
post FMT (i). OPLS-DA scores plots of pre- and post FMT (ii, Q2Y < 0, p > 0.05), donors and patients at 
pre-FMT (iii, Q2Y = 0.81, p = 0.001), and donors and patients at post-FMT (iv, Q2Y = 0.72, p = 0.04).  
(B) O-PLS-DA loadings plots of 1H NMR profiles of fresh faecal water samples from donors and patients 
at pre-FMT (i) and donors and patients at post-FMT (ii). Peaks pointing upwards represent higher levels of 
metabolites in patients compared with donors and vice versa. The colours of peaks represent the correlation 
(r2) between the metabolites and the classification (e.g. patients or donors).
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previously shown to be increased in the epithelium of UC and CD patients40 and Clostridiaceae are asso-
ciated with pouch inflammation (37). Furthermore, potentially beneficial bacterial groups were increased 
in proportional abundance in some individuals following FMT. For example, Faecalibacterium prauznitzii 
is reduced in colitis patients41 and has anti-inflammatory properties, Dorea has been associated with 
non-inflammatory pouch outcomes7 and a recent study associated increased abundance of Sutterella 
with pouch health7. It is of interest therefore that, despite these potentially beneficial shifts, no significant 
improvement in clinical outcome was detected.
Faecal metabolic profiles of patients with pouchitis were also similar to those of IBD patients reported 
previously42 and were characterized by higher levels of amino acids (e.g. alanine, isoleucine, leucine) and 
lower levels of short chain fatty acids in patients compared with non-IBD controls43. Porphyromonadaceae 
were positively correlated with elevated short chain fatty acid production, fumarate and uracil and nega-
tively correlated with histamine, succinate and lactate. The higher abundance of Porphyromonadaceae in 
the donors or in healthy gut is in agreement with previous studies44. However, we did not observe any 
significant increase in Porphyromonadaceae post FMT and no significant metabolic changes in patients 
pre- and post-FMT were identified despite changes in the microbiota in some patients.
Abundant molecular functions are not necessarily provided by abundant species45 and core metabolic 
functions may be shared between bacteria, promoting stability in metabolic function, and maintaining 
homeostasis. Consequently, the changes in the microbiota that were demonstrated post FMT might not 
lead to significant metabolic and subsequently immunological changes.
The diversity of the pouch microbiota was reduced in the faecal samples, but not in the mucosal sam-
ples at baseline. This is an unexpected finding, but may represent the severity and longevity of inflam-
mation in the mucosa of the patients included. Chronic inflammation may enable the residual mucosal 
microbiota to create a niche with reasonable diversity, whilst the high pouch frequency in these patients 
could decrease the stability of the faecal/luminal microbiota. Previous studies suggest a higher richness 
of the mucosal microbiota than the faecal microbiota with a greater impact on the diversity of the faecal 
compared with mucosal microbiota as a consequence of osmotic diarrhoea46. Higher species richness 
(“biodiversity”), enhances the robustness and stability of an ecosystem and might be an intrinsic safe-
guard against perturbations47.
The pouch frequency, and longevity/severity of inflammation in our patient cohort may explain the 
poorer outcomes in this study compared with a recent randomised study of FMT in UC patients26. 
Patients with milder or quiescent disease may therefore be more amenable to durable alteration of the 
microbiota with FMT. In the recent randomised studies of FMT in UC, the faecal microbiota following 
FMT showed greater diversity and there was a shift in responders towards a “healthier” composition of 
the microbiota. Whilst baseline Mayo score did not impact on treatment success, disease duration ≤ 1 
year did impact on treatment success26. However, in another recent randomised study of FMT in patients 
with mild to moderate disease there was no significant clinical impact of FMT27.
There are also a number of possible methodological explanations for the lack of efficacy of FMT in 
this study compared with other recent studies. FMT was performed via a nasogastric tube in accordance 
with previously reported protocols for recurrent Clostridium difficile infection48,49 and indeed, the recently 
reported randomised controlled trial of FMT for recurrent Clostridium difficile employed nasoduodenal 
administration where benefit was demonstrated18. However, nasogastric tube delivery may not be the 
optimal mode of delivery for IBD patients. Colonic administration of donor stool was efficacious in 
reports of FMT for IBD50 and this may be a preferred and improved route of delivery for IBD patients. 
In the recent randomised studies of FMT for UC, where faecal enemas were used there was a significant 
difference in the proportion of patients in clinical remission compared with placebo26; whilst in the study 
using nasojejunal administration there was no significant difference between FMT from healthy donors 
and autologous FMT27. Previous reports of FMT for IBD also report the use of more frequent infusions, 
which may be necessary for more robust engraftment of donor microbiota. It is also unknown whether 
pre-treatment with bowel lavage and antibiotics is necessary, although in an animal model of FMT, anti-
biotics were not necessary to establish engraftment of exogenous microbiota51.
It is also possible that the microbiota from the donors used was suboptimal. Several of the donors 
were relatives or household contacts of the recipients. Relatives of patients with IBD have been shown to 
have alterations in their microbiota distinguishing them from other “healthy” donors52. In the two recent 
randomised studies of FMT in UC the majority of donors were unrelated26,27. The study by Moayyedi 
et al. also demonstrated differences in response depending on the donor used, with the majority of 
responders having received FMT from the two donors with similar microbiota profiles26. A study of FMT 
in mice showed that successful alteration of the recipient’s microbiota depended on the donor microbi-
ota being both phylogenetically diverse and distinct from that of the recipient53. Here, donors were not 
selected in this way. Furthermore, the donor microbiota used here may not be applicable to the niche of 
the UC pouch and perhaps UC or familial adenomatous polyposis ileal pouch patients without a history 
of pouchitis would be a more appropriate donor in this context. However, no data are currently available 
regarding the optimal route of administration, volume or frequency of faecal infusion, adjunctive thera-
pies or optimal properties of donor stool for either Clostridium difficile or IBD.
We conclude that a single FMT from a healthy donor by nasogastric delivery to patients with chronic 
pouchitis resulted in variable changes in microbiota composition, which were insufficient to impact on 
the microbiota function, mucosal immune responses or lead to clinical response for patients. This study 
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demonstrates the necessity of functional as well as phylogenetic analysis of the microbiota following 
FMT.
This also raises several questions regarding FMT in IBD. What is the most appropriate protocol regard-
ing route of administration, frequency of infusions and pre-treatment interventions? Which donors are 
most appropriate microbiologically? In which patient group will FMT be most effective - acute or chronic 
active disease, once remission has been induced by standard therapies or as a prophylactic approach? 
Is engraftment of particular species or a complex community that alters microbiota diversity necessary 
for effective functional change of the microbiota that has immunological and clinical sequelae? Further 
studies investigating the functionality of the microbiota post FMT in conjunction with immunological 
assessment post FMT are required to address these issues.
Methods
The methods were carried out in accordance with ethical approval from local ethics committee (North 
London REC 2 EC no. 11/LO/0170) and all patients and donors gave their written informed consent. 
All experimental protocols were approved by NHS Research and Development at North West London 
Hospitals NHS Trust.
We conducted a pilot study of FMT in patients with chronic pouchitis diagnosed clinically, endo-
scopically and histologically, with a current pouch disease activity index (PDAI) ≥ 754. Healthy donors 
included relatives, partners or anonymous unrelated donors. A single nasogastric infusion of donor fae-
ces was given according to previously described protocols48,49 (Supplementary Methods). Briefly, donor 
stool was provided within six hours prior to faecal transplantation. 30 g of stool was homogenised with 
50 ml of 0.9% saline to produce a faecal-saline solution and 30 ml of the faecal-saline solution was admin-
istered via the nasogastric tube.
Assessment before FMT consisted of clinical (PDAI and Cleveland global quality of life scores), endo-
scopic and histological assessment. Stool was also collected for analysis of faecal coliform sensitivities as 
previously described55. Stool and biopsies were collected for microbiological and metabonomic assess-
ments and biopsies were collected for immunological assessments. These assessments were repeated four 
weeks following FMT (Supplementary Methods).
Microbiota analysis. DNA was extracted, 16S rRNA gene PCR amplicons generated, and 454 pyrose-
quencing carried out as described previously56, except that Q5TM Taq polymerase (New England Biolabs) 
was used for PCR reactions and 25 PCR cycles were used. “Blank” DNA extractions were processed con-
currently, and were sequenced to monitor background contaminating bacterial species that were present 
in kits/laboratory reagents. All identified contaminant OTUs (Supplementary Table 3) were removed 
prior to further analyses.
Amplicons from each sample were pooled into an equimolar mix and then sequenced with the 
Lib-L kit using the 454 GS FLX Titanium platform. The 454 pyrosequence data has been deposited 
at the European Nucleotide Archive under Study Accession Number ERP005254/ Sample Accession 
Number ERS421606. The Golay barcode sequences used for each sample in the study are listed in the 
Supplementary Methods. 16S rRNA gene sequences were analysed, and Non-metric multidimensional 
scaling (NMDS) plot, dendrograms and AMOVA values calculated using the mothur software package57. 
OTUs and higher taxa that were differentially abundant between cohorts were assessed by Metastats58, 
as applied in mothur. Significance threshold levels were adjusted to mitigate against false discovery rate 
using the Benjamini-Hochberg method59 (Supplementary Methods).
1H NMR spectroscopy. 1H NMR spectra of both fresh faecal water and dried faecal samples obtained 
from donors and patients at pre- and post-FMT were acquired using a Bruker 600 MHz spectrometer 
(Bruker, Rheinstetten, Germany) at the operating 1H frequency of 600.13 MHz at a temperature of 300 K. 
A standard NMR pulse sequence (recycle delay-90°-t1-90°-tm-90°-acquisition) was used to obtain stand-
ard one-dimensional 1H NMR spectral data, where t1 was set to 3 ms and tm (mixing time) was set to 
100 ms. The water peak suppression was achieved using selective irradiation during a recycle delay of 2 s 
and tm. A 90 degree pulse was adjusted to 10 μ s. A total of 128 scans were collected into 64 k data points 
with a spectral width of 20 ppm (Supplementary Methods).
1H NMR spectra of faecal water samples were automatically phased, referenced to TSP at d1H 0.00 and 
baseline-corrected using an in-house developed MATLAB script (Supplementary Methods). Probabilistic 
quotient normalization was subsequently performed on the datasets in order to account for dilution of 
complex biological mixtures. Principal component analysis (PCA) and orthogonal partial least squares 
discriminant analysis (OPLS-DA) were carried out in SIMCA (P + 13.0) and MATLAB software in order 
to gain an overview of the variation in the spectral dataset and classification-related (e.g. donors vs. 
patients, pre-FMT vs. post-FMT) metabolic changes respectively.
OPLS regression analysis was used to correlate metabolic data with microbial profiles. Fifteen groups 
of bacteria at the family levels, each present in greater than 10 samples, were selected for correlation anal-
ysis (Lachnospiraceae, Bacteroidaceae, Enterobacteriaceae, Prevotellaceae, Ruminococcaceae, Clostridiaceae, 
Lactobacillaceae, Peptostreptococcaceae, Sutterellaceae, Erysipelotrichaceae, Porphyromonadaceae, 
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Rikenellaceae, Streptococcaceae, Pasteurellaceae, Veillonellaceae) as well as unclassified Clostridiales, and 
then all remaining unclassified Firmicutes.
Isolation of lamina propria dendritic cells and cell surface labelling. The method used has been 
described and validated previously29,60,61. Cells were labelled in FACS buffer (phosphate-buffered saline 
containing 1 mmol/L EDTA and 0.02% sodium azide). To prevent non-specific binding, unoccupied 
binding sites were blocked with foetal calf serum prior to antibodies being added at predetermined 
optimal concentrations (Supplementary Methods).
Cytokines in whole biopsy culture supernatants. Cell-free culture supernatants were analysed 
using a multiplex assay (BD Cytometric Bead Array) according to the manufacturer’s instructions to 
determine levels of IL-6 and TNF in biopsy supernatants.
Flow Cytometry. Data were acquired using a FACSCanto II flow cytometer (BD Biosciences, Oxford, 
England). Isotype matched controls were used for all markers assessed using multicolour analysis DCs 
were identified as an HLA-DR+ lineage– (CD3–, CD14–,CD16–,CD19–,CD34–) population. Surface 
markers (TLR 2, 4 and 5, CCR 9, integrin β 7 and CD40) were assessed using flow cytometric analysis. 
Super-enhanced Normalised Subtraction WinList version 5 software (Verity Software House, Maine) was 
used to measure the percentage of positive staining cells and the level of staining for cell surface markers 
as previously described29,62,63.
Statistical Analysis. Clinical data are presented as median with range. Dendritic cell surface marker 
and cytokine expression data are shown as mean ± SEM. Wilcoxon signed rank test was used to compare 
clinical and immunological data pre- and post- faecal transplantation.
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